Neuroscience and technology firm electroCore has commercially launched its non-invasive vagus nerve stimulator gammaCore in the US, to acutely treat pain associated with episodic cluster headache in adults.

The hand-held medical device can be applied to the neck to send mild electrical stimulation through the skin for stimulation of afferent fibres of the vagus nerve that in turn causes mitigation of the pain.

gammaCore is a portable, easy-to-use technology, which can be self-administered without potential side effects that are usually observed during standard of care.

electroCore CEO Francis Amato said: “It provides episodic cluster headache sufferers with a much-needed treatment option for this rare and often debilitating condition.

“The commercial launch also signifies an important milestone for electroCore, marking the first marketed product for the company in the US.”

"It provides episodic cluster headache sufferers with a much-needed treatment option for this rare and often debilitating condition."

The US Food and Drug Administration (FDA) released the vagus nerve stimulator in April and granted 510(k) clearance for commercialisation in the country in June.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

gammaCore is accessible to the patients who are enrolled in a non-research registry called gammaCore Patient Registry (GPR) established at select headache centres in the country to assess patient experience with the device.

The registered patients will be eligible to receive gammaCore treatment over a period of two months at free of cost and are required to share their experience, as well as information on periodic quality-of-life and self-reported outcomes.

GPR additionally offers an online tracker to record cluster attacks, training from a GPR coordinator on gammaCore use, and access to support from a care specialist during the treatment period.

Image: gammaCore. Photo: courtesy of PRNewsfoto/electroCore LLC.